

NEW AGENTS AND EMERGING STRATEGIES IN THE MANAGEMENT OF EARLY AND ADVANCED BREAST CANCER

An Interactive Grand Rounds Series

CME Information

TARGET AUDIENCE

This activity is intended for medical oncologists and other healthcare providers involved in the treatment of breast cancer.

OVERVIEW OF ACTIVITY

The pace of oncology drug development has accelerated in recent years to previously unmatched levels. Fueled by an increased understanding of the biologic underpinnings of tumor development and progression, clinical research platforms largely focused on evaluating the potential benefits of novel targeted therapeutics possessing unique mechanisms of action and safety profiles have led to improved outcomes in myriad large and rigorous clinical trials across many different tumor types. The successes yielded by this rational approach to the design and evaluation of new therapies have in turn provided medical oncologists and patients with many additional and beneficial FDA-endorsed treatment options. Although this dynamic appears to be prevalent in many corners of oncology, scientific and clinical advancements in the treatment of breast cancer have made it particularly pronounced in this area.

To bridge the gap between research and patient care, this video presentation by Dr Joyce O'Shaughnessy uses a review of recent relevant publications and presentations, ongoing clinical trials and clinical investigator treatment preferences to assist medical oncologists and other healthcare providers involved in the treatment of breast cancer with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

- Review emerging research data evaluating the use of anti-HER2 therapies to reduce the residual risk of relapse for patients with localized HER2-positive breast cancer receiving adjuvant trastuzumab/chemotherapy.
- Develop an understanding of the mechanism of action of, available Phase III data with and current role of recently approved CDK4/6 inhibitors for the management of advanced ER-positive breast cancer.
- Recall available efficacy and safety data with PARP inhibitors in patients with BRCA mutation-positive,

HER2-negative metastatic breast cancer, and consider the diagnostic and therapeutic implications of these findings for clinical care.

- Appraise the rationale for and clinical data with investigational anti-PD-1/PD-L1 antibodies for patients with metastatic breast cancer, and use this understanding to prioritize clinical trial opportunities for appropriate individuals eligible for participation.
- Identify ongoing trials of other investigational approaches in breast cancer, and refer patients and obtain consent for study participation.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 1.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: **medical oncology**.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share

or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at [ResearchToPractice.com/Privacy-Policy](https://www.researchtopractice.com/Privacy-Policy) for more information.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at [ResearchToPractice.com/GrandRoundsBreast18/CME](https://www.researchtopractice.com/GrandRoundsBreast18/CME).

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Presenting Faculty Member

Joyce O'Shaughnessy, MD

Chair, Breast Cancer Research Program
Baylor Charles A Sammons Cancer Center
Celebrating Women Chair in Breast Cancer Research
Texas Oncology
US Oncology
Dallas, Texas

Advisory Committee: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme; **Consulting Agreements:** AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Genomic Health Inc, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme; **Contracted Research:** Takeda Oncology.

Project Steering Committee

Kimberly L Blackwell, MD

Professor of Medicine
Director, Breast Cancer Program
Duke Cancer Institute
Durham, North Carolina

Advisory Committee: Advaxis Inc, Bayer HealthCare Pharmaceuticals, Eisai Inc, MacroGenics Inc, Merck, Novartis, Pfizer Inc, Pierian Biosciences, Syndax Pharmaceuticals Inc; **Consulting Agreements:** Celgene Corporation, Coherus Biosciences, G1 Therapeutics, Genentech, Lilly, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Sandoz; **Contracted Research:** Celgene Corporation, Genentech, Novartis, Pfizer Inc.

Harold J Burstein, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

No relevant conflicts of interest to disclose.

William J Gradishar, MD

Betsy Bramsen Professor of Breast Oncology and Professor of Medicine
Deputy Director, Clinical Network
Robert H Lurie Comprehensive Cancer Center of Northwestern University
Director, Maggie Daley Center for Women's Cancer Care
Interim Chief, Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

No relevant conflicts of interest to disclose.

Sara A Hurvitz, MD

Associate Professor of Medicine
Director, Breast Oncology Program, Division of Hematology/Oncology
University of California, Los Angeles
Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
Los Angeles, California
Co-Director, Santa Monica-UCLA Outpatient Oncology Practices
Santa Monica, California

Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, BioMarin Pharmaceutical Inc, Boehringer Ingelheim Pharmaceuticals Inc, Cascadian Therapeutics, Dignitana AB, Genentech, GlaxoSmithKline, Lilly, Medivation Inc, a Pfizer Company, Merrimack Pharmaceuticals Inc, Novartis, OBI Pharma Inc, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Seattle Genetics; **Paid Travel:** Bayer HealthCare Pharmaceuticals, Lilly, Novartis, OBI Pharma Inc.

Ruth M O'Regan, MD

Professor of Medicine
Chief, Division of Hematology/Oncology
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Advisory Committee: Genentech, Genomic Health Inc, Lilly, Novartis, Pfizer Inc; **Contracted Research:** Eisai Inc, Novartis, Pfizer Inc.

Mark D Pegram, MD

Susy Yuan-Huey Hung Professor of Medicine
Director of the Breast Oncology Program
Associate Dean, Clinical Research Quality
Associate Director for Clinical Research
Stanford Cancer Institute
Stanford University School of Medicine
Stanford, California

Advisory Committee and Consulting Agreements: Amgen Inc, Genentech, Novartis, Pfizer Inc, Roche Laboratories Inc.

Joseph A Sparano, MD

Professor of Medicine and Women's Health
Albert Einstein College of Medicine
Associate Chairman, Department of Oncology
Montefiore Medical Center
Bronx, New York

Consulting Agreements: Genentech, Lilly, Pfizer Inc;

Contracted Research: Atossa Genetics Inc, Deciphera Pharmaceuticals LLC, Genentech, GlaxoSmithKline, Merck, Novartis, Prescient Therapeutics Pty Ltd, Takeda Oncology; **Ownership**

Interest: MetaStat Inc.

PROJECT CHAIR — **Dr Love** is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc,

Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL

REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, Lilly and Tesaro Inc.

Hardware/Software Requirements:

A high-speed Internet connection

A monitor set to 1280 x 1024 pixels or more

Internet Explorer 11 or later, Firefox 56 or later,

Chrome 61 or later, Safari 11 or later, Opera 48 or later

Adobe Flash Player 27 plug-in or later

Adobe Acrobat Reader

(Optional) Sound card and speakers for audio

Release date: June 2018

Expiration date: June 2019

Select Publications

- Adams S et al. **Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.** *Proc ASCO 2017*;Abstract 1008.
- Adams S et al. **Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).** *Proc ASCO 2016*;Abstract 1009.
- Barcenas C et al. **Incidence and severity of diarrhea with neratinib + intensive loperamide prophylaxis in patients (pts) with HER2+ early-stage breast cancer (EBC): Interim analysis from the multicenter, open-label, phase II control trial.** San Antonio Breast Cancer Symposium 2016;Abstract P2-11-03.
- Chan A et al; ExteNET Study Group. **Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.** *Lancet Oncol* 2016;17(3):367-77.
- Delalogue S et al. **OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice.** *Proc ESMO 2017*;Abstract 243PD.
- Dickler MN et al. **MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.** *Clin Cancer Res* 2017;23(17):5218-24.
- Finn RS et al. **Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18).** *Proc ASCO 2017*;Abstract 1001.
- Finn RS et al. **Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.** *Breast Cancer Res* 2016;18(1):17.
- Finn RS et al. **The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study.** *Lancet Oncol* 2015;16(1):25-35.
- Goetz M et al. **MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer.** *J Clin Oncol* 2017;35(32):3638-46.
- Hortobagyi GN et al. **Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC).** *Proc ASCO 2017*;Abstract 1038.
- Hortobagyi GN et al. **Ribociclib as first-line therapy for HR-positive, advanced breast cancer.** *N Engl J Med* 2016;375(18):1738-48.
- Jimenez M et al. **Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5 year analysis of the phase III ExteNET trial.** *Proc ESMO 2017*;Abstract 1490.
- Konstantinopoulos PA et al. **Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162).** *Proc ESMO 2017*;Abstract 1143PD.
- Litton JK et al. **EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation.** San Antonio Breast Cancer Symposium 2017;Abstract GS6-07.
- Robson M et al. **Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.** *N Engl J Med* 2017;377(6):523-33.
- Robson M et al. **OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).** *Proc ASCO 2017*;Abstract LBA4.
- Schmid P et al. **Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses.** *Proc AACR 2017*;Abstract 2986.
- Sledge GW Jr et al. **MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy.** *J Clin Oncol* 2017;35(25):2875-84.
- Tripathy D et al. **First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial.** San Antonio Breast Cancer Symposium 2017;Abstract GS2-05.
- von Minckwitz G et al; APHINITY Steering Committee and Investigators. **Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer.** *N Engl J Med* 2017;377(2):122-31.
- von Minckwitz G et al. **APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).** *Proc ASCO 2017*;Abstract LBA500.